EIGR
Price:
$1.725
Market Cap:
$12.59M
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clini...[Read more]
Industry
Biotechnology
IPO Date
2014-01-30
Stock Exchange
NASDAQ
Ticker
EIGR
According to Eiger BioPharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 28.35M. This represents a change of -32.04% compared to the average of 41.72M of the last 4 quarters.
The mean historical Enterprise Value of Eiger BioPharmaceuticals, Inc. over the last ten years is 152.94M. The current 28.35M Enterprise Value has changed 1.75% with respect to the historical average. Over the past ten years (40 quarters), EIGR's Enterprise Value was at its highest in in the September 2022 quarter at 344.69M. The Enterprise Value was at its lowest in in the December 2023 quarter at 26.19M.
Average
152.94M
Median
104.24M
Minimum
26.17M
Maximum
349.53M
Discovering the peaks and valleys of Eiger BioPharmaceuticals, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 220.63%
Maximum Annual Enterprise Value = 349.53M
Minimum Annual Increase = -65.94%
Minimum Annual Enterprise Value = 26.17M
Year | Enterprise Value | Change |
---|---|---|
2023 | 26.17M | -58.80% |
2022 | 63.52M | -65.94% |
2021 | 186.49M | -46.65% |
2020 | 349.53M | 5.16% |
2019 | 332.38M | 220.63% |
2018 | 103.66M | -1.10% |
2017 | 104.81M | 84.03% |
The current Enterprise Value of Eiger BioPharmaceuticals, Inc. (EIGR) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
92.06M
5-year avg
191.62M
10-year avg
152.94M
Eiger BioPharmaceuticals, Inc.’s Enterprise Value is greater than Spero Therapeutics, Inc. (-20557187.00), less than Bolt Biotherapeutics, Inc. (28.60M), less than Coherus BioSciences, Inc. (304.45M), less than Gracell Biotechnologies Inc. (5.66B), greater than Neoleukin Therapeutics, Inc. (-6333315.00), greater than Cingulate Inc. (5.64M), greater than Lyra Therapeutics, Inc. (22.74M), less than Finch Therapeutics Group, Inc. (29.54M), greater than Applied Therapeutics, Inc. (4.58M), less than X4 Pharmaceuticals, Inc. (82.45M), less than Acumen Pharmaceuticals, Inc. (103.75M), less than Inozyme Pharma, Inc. (209.16M), less than Terns Pharmaceuticals, Inc. (219.57M), less than Day One Biopharmaceuticals, Inc. (851.52M), greater than Connect Biopharma Holdings Limited (-53600395.00), less than Eton Pharmaceuticals, Inc. (312.27M), less than Nuvation Bio Inc. (891.57M), less than Eledon Pharmaceuticals, Inc. (247.04M), greater than Spruce Biosciences, Inc. (-40312221.00), greater than Werewolf Therapeutics, Inc. (-18312936.00), less than Unicycive Therapeutics, Inc. (39.02M), less than Fusion Pharmaceuticals Inc. (1.87B),
Company | Enterprise Value | Market cap |
---|---|---|
-20557187.00 | $51.11M | |
28.60M | $19.79M | |
304.45M | $170.52M | |
5.66B | $989.87M | |
-6333315.00 | $8.20M | |
5.64M | $15.45M | |
22.74M | $11.22M | |
29.54M | $16.59M | |
4.58M | $101.47M | |
82.45M | $101.66M | |
103.75M | $106.94M | |
209.16M | $186.94M | |
219.57M | $488.40M | |
851.52M | $1.27B | |
-53600395.00 | $56.25M | |
312.27M | $332.40M | |
891.57M | $910.41M | |
247.04M | $253.29M | |
-40312221.00 | $16.51M | |
-18312936.00 | $67.74M | |
39.02M | $70.56M | |
1.87B | $1.83B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Eiger BioPharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Eiger BioPharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Eiger BioPharmaceuticals, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Eiger BioPharmaceuticals, Inc. (EIGR)?
What is the 3-year average Enterprise Value for Eiger BioPharmaceuticals, Inc. (EIGR)?
What is the 5-year average Enterprise Value for Eiger BioPharmaceuticals, Inc. (EIGR)?
How does the current Enterprise Value for Eiger BioPharmaceuticals, Inc. (EIGR) compare to its historical average?